The Science Behind CREGEN — Creatine, Cellular Energy & the CGG Amino-Bridge™
Free shipping on orders $149+  ·  Shop Now 30-Day Money-Back Guarantee South Korean Science. Made in USA. CGG Amino-Bridge™ Technology · KAIST + EIMEC Validated Free shipping on orders $149+  ·  Shop Now 30-Day Money-Back Guarantee South Korean Science. Made in USA. CGG Amino-Bridge™ Technology · KAIST + EIMEC Validated
Evidence-Based Performance Science

CREGEN Scientific

Knowledge that moves human performance forward. An honest look at creatine, cellular energy, and the CGG Amino-Bridge™ — pairing creatine monohydrate with glycine and glutamine for better absorption and retention.

🇰🇷 KAIST — Origin of the early research 🇪🇺 EIMEC Barcelona — Independent pilot Preliminary · Exploratory
Shop CREGEN 30-day money-back guarantee
From the Research Team

To the reader,

CREGEN did not begin in a marketing department. It began in a laboratory at KAIST — Korea's leading institute of science and technology — with a single question: why does creatine, one of the most studied compounds in human performance, barely reach the brain?

The answer guiding the CGG Amino-Bridge™ was simple: pair creatine monohydrate with the amino acids glycine and glutamine to improve how much the body absorbs and retains. The early research approach originated at KAIST; an independent institute (EIMEC) in Barcelona later ran a small pilot to measure retention in a separate cohort.

We believe performance science should be honest about its limits. The human data here comes from one small, preliminary pilot — not a finished clinical program. We report what it actually measured, including the results that were only directional.

Two institutions. Two roles: KAIST — origin of the early research. EIMEC — independent pilot measurement.

With rigor, Dr. Jo Su-Yeon, Ph.D. Lead Researcher · CGG Amino-Bridge™ · KAIST
56%
Lower Urinary Creatine Loss
vs competitor · pilot, p=0.028
15 Days
Pilot Duration
5g/day · independent EIMEC pilot
+23%
Higher Serum Creatine
directional trend (not significant)
ATP
Cellular Energy Currency
creatine's well-documented role
In Plain English

What does "better absorption and retention" actually mean?

Creatine is one of the most studied compounds in human performance, with a well-documented role in cellular energy — it helps regenerate ATP, the energy currency your cells run on, in tissues with high demand like muscle and the brain. The practical challenge is absorption and retention: how much of each dose your body actually keeps and uses. CREGEN's CGG Amino-Bridge™ pairs creatine monohydrate with glycine and glutamine with the goal of improving that retention. In an independent EIMEC pilot, this showed up as roughly 56% lower urinary creatine loss versus a competitor (preliminary, p=0.028) — meaning less was wasted.

1
Creatine fuels cellular energy
Creatine's established role is replenishing ATP — the energy your cells spend — which is why it's so widely studied for both physical and mental performance.
2
The CGG Amino-Bridge™
Pairing creatine monohydrate with glycine and glutamine is designed to improve how much of each dose is absorbed and retained, rather than excreted.
56%
Less creatine wasted
The one statistically significant pilot result: ~56% lower urinary creatine loss vs a competitor (preliminary, p=0.028). Larger studies are still needed.
🇰🇷
KAIST Research
Developed at the Korea Advanced Institute of Science and Technology — South Korea's premier research institution.
🧠
Better Absorption
CGG Amino-Bridge™ pairs creatine with glycine and glutamine to improve absorption and retention — in an independent pilot, ~56% less was lost in urine.
⚡
ATP & Energy Support
Neurons replenish ATP reserves directly. Sharper focus, faster thinking, reduced mental fatigue.
✅
Safe & Clean Formula
GMP Certified · Third-Party Tested · No artificial additives · Zero bloating · Zero loading phase required.
Grounded in the Broader Creatine Literature
🏛️
KAIST
📗
nature portfolio
📘
Frontiers in Nutrition
📙
PLOS ONE
🇪🇺
EIMEC Barcelona
See All References
Two Institutions, Two Roles

Originated in Korea. Tested in Europe.

The CGG Amino-Bridge™ approach traces back to early research at KAIST. EIMEC, an independent European institute, later ran a small, preliminary pilot to measure absorption and retention in a separate cohort. Here is exactly who did what — and what the data can and can't yet say.

🇰🇷
Discovered & Developed it
KAIST
Korea Advanced Institute of Science & Technology · Daejeon, South Korea

KAIST is South Korea's leading institute of science and technology — and the origin of the early research behind CREGEN's approach. This is where the CGG Amino-Bridge™ concept took shape: pairing creatine monohydrate with glycine and glutamine to improve absorption, retention, and bioavailability.

Originated the approach: the CGG Amino-Bridge concept — creatine paired with glycine and glutamine.
Focused on bioavailability: improving how much creatine the body absorbs and retains.
Dr. Jo's work: B.S., M.S. and Ph.D. all earned at KAIST; principal researcher on the formulation.
Independently
tested by
🇪🇺
Independently Tested it
EIMEC
European Institute of Medical & Exercise Cognition · Barcelona, Spain

EIMEC had nothing to do with creating CREGEN — and that's the point. As an independent third party in Europe, EIMEC ran a small, preliminary bioavailability pilot (n=2–3 per group, 5g/day for 15 days) comparing CREGEN to competitors, with no stake in the outcome. The one statistically significant result was ~56% lower urinary creatine loss vs a competitor (p=0.028); serum and plasma trends pointed the same direction but were not significant.

Outside testing: an unaffiliated European lab, not the developers measuring their own product.
Separate cohort: a small European pilot group, distinct from the original research.
Measured retention: significantly lower urinary creatine loss vs a competitor (preliminary; larger studies needed).
Research Index

The studies behind the formula.

Each entry traces a specific claim back to its source — the mechanism, the methodology, and the measured result. Full summaries are available to clinicians and partners on request.

Dossiers

Read the research.

Compiled study summaries and methodology dossiers — open access, in the spirit of independent science.

CGG Amino-Bridge™ Dossier
Methodology · KAIST Discovery
The Approach
How the CGG Amino-Bridge™ improves absorption & retention
Summary on request
EIMEC Bioavailability Study
🇪🇺 Barcelona · EU Cohort
The Validation
Independent EU bioavailability data
Summary on request
Creatine & Cellular Energy
ATP · Phosphocreatine · Published Literature
The Background
Creatine's well-documented role in ATP regeneration
Established science
Lead Researcher

Dr. Jo Su-Yeon, Ph.D.

Ph.D. Chemistry · KAIST · Postdoctoral Researcher · Samsung SDI R&D

Dr. Jo Su-Yeon is the principal researcher behind the CGG Amino-Bridge™ approach. Her work at KAIST on creatine and amino-acid pairing shaped a formulation designed to improve how much creatine the body absorbs and retains. All three degrees — B.S., M.S., and Ph.D. — earned at KAIST.

🇰🇷 Developed in South Korea — NOT China

CREGEN's formulation was researched and developed exclusively in South Korea at KAIST — a country recognized globally for rigorous scientific standards, pharmaceutical precision, and biotechnology innovation. The CGG technology is backed by South Korean intellectual property and conducted entirely independent of Chinese manufacturing or research.

B.S.
Undergraduate
B.S. in Chemistry — KAIST
Korea Advanced Institute of Science and Technology, Daejeon, South Korea
M.S.
Graduate
M.S. in Chemistry — KAIST
Specialization in molecular transport mechanisms and bioavailability enhancement
Ph.D
Doctoral
Ph.D. in Chemistry — KAIST
Dissertation focused on creatine transporter proteins and CGG Amino-Bridge pathway discovery
Post
Postdoctoral
Postdoctoral Researcher — KAIST
Lead researcher on CGG patent development and formulation design
R&D
Industry
R&D Researcher — Samsung SDI
Advanced materials research; expertise in molecular formulation and delivery systems applied to nutrition science
Dr. Jo Su-Yeon — Korean scientist, Lead Researcher at KAIST
🇰🇷 KAIST · Daejeon, South Korea
3
Degrees in Chemistry — Creatine & Amino-Acid Research at KAIST
1
Active Patent: CGG Amino-Bridge System (KR-2023-0118)
B·M·D
All Degrees Earned at KAIST, South Korea
🔬
Samsung SDI R&D — Advanced Molecular Research
🇪🇺
Independent
EU Validated
Independent EU Pilot

EIMEC Bioavailability Pilot

The European Institute of Medical and Exercise Cognition — EIMEC, based in Barcelona, Spain — ran a small, independent pilot (n=2–3 per group, 5g/day for 15 days) comparing CREGEN with competitors. EIMEC did not develop CREGEN. The study found one statistically significant result — lower urinary creatine loss — alongside directional, non-significant trends in serum and plasma. Findings are preliminary and exploratory; larger studies are needed to confirm them.

56%
Lower Urinary Loss
The one statistically significant result: ~56% less creatine lost in urine vs a competitor (p=0.028) — better retention
+23%
Serum Creatine
Directional trend toward higher serum creatine — not statistically significant
+26%
Plasma Creatine
Directional trend toward higher plasma creatine — not statistically significant
n=2–3
Per Group
A small, preliminary pilot — 5g/day for 15 days. Exploratory; larger studies are needed to confirm
Lower urinary creatine loss confirmed (pilot, p<0.05)
Directional gains in serum & plasma (not significant)
EU cohort · controlled pilot study
Barcelona, Spain — EU-registered lab
Research & References

The figures on this page are drawn from early KAIST research, the small independent EIMEC bioavailability pilot, and the published literature on creatine's role in cellular energy. We believe science should be honest about its limits: the human data here is preliminary and exploratory, and larger studies are needed. Full pilot summaries — covering methodology, cohort details, and the data behind every figure — are available to verified retail partners, practitioners, and customers on request.

Request the full research summaries
Common Questions

Your Questions, Answered

The questions we hear most often about how CREGEN works and the science behind it.

Q.What's the difference between KAIST and EIMEC?
Simple: KAIST is the origin of the early research; EIMEC independently tested it. KAIST — the Korea Advanced Institute of Science and Technology — is where the CGG Amino-Bridge approach was developed. EIMEC, an independent institute in Barcelona, ran a small, preliminary pilot on a separate European group to measure absorption and retention from the outside. One originated the approach; the other measured it.
Q.How is CREGEN different from regular creatine?
Standard creatine monohydrate is effective but a meaningful share of each dose is excreted rather than retained. CREGEN's CGG Amino-Bridge™ pairs creatine with glycine and glutamine to improve absorption and retention — in an independent pilot, roughly 56% less creatine was lost in urine versus a competitor (preliminary, p=0.028). The aim is to get more out of each dose, supporting creatine's well-documented role in cellular energy for both body and mind.
Q.Do I need a loading phase or large doses?
No. Because more of each dose actually reaches its target, CREGEN is designed to work at a lower effective dose — one sachet a day. There's no loading phase, no megadosing, and no waiting weeks to "saturate." Just mix and go.
Q.Will it cause bloating or stomach discomfort?
CREGEN is formulated to be gentle on the gut. The improved absorption means a smaller, better-utilized dose — which is why testing pointed to far less waste and the elimination of the GI discomfort many people associate with traditional creatine loading.
Q.When will I notice a difference?
Everyone is different, and individual results vary. CREGEN is grounded in creatine's well-documented role in cellular energy; the EIMEC pilot focused on bioavailability and retention rather than a CREGEN-specific cognitive trial. Most people use it daily and assess how they feel over a full sachet supply.
Q.Is it made in China?
No. The CGG technology was researched and developed exclusively in South Korea at KAIST, backed by South Korean intellectual property and conducted entirely independent of Chinese manufacturing or research. The finished product is made in the USA under GMP-certified, third-party-tested standards.
Q.How do you back up the claims on this page?
Every figure shown here comes from the KAIST research program, the independent EIMEC study, or the peer-reviewed publications cited above — not internal marketing. Full study summaries are available on request so you can read the methodology and data for yourself.
Built on Creatine, Done Honestly

Ready to Experience the Difference?

One sachet a day. Better retention in an independent pilot — backed by a 30-day money-back guarantee.

Shop CREGEN Read the Research

* EIMEC data based on an independent controlled pilot study (small EU cohort, 5g/day for 15 days). Results are preliminary and exploratory; larger studies are required to confirm. Individual results may vary. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.